Chronic radiation myelitis

Area of Science:

• Oncology
• Radiation Oncology
• Neurology

Background:

• Split-course accelerated fractionation was used for primary bronchogenic carcinoma treatment.
• This technique involves delivering 4,000 rad (40 Gy) over a specific period.
• Concerns exist regarding the resurgence of rapid fractionation methods in cancer treatment.

Purpose of the Study:

• To review the authors' experience with split-course accelerated fractionation for lung cancer.
• To analyze the incidence of progressive myelitis following this radiation therapy.
• To discuss current understanding of factors influencing radiation-induced myelitis.

Main Methods:

• Retrospective analysis of 200 patients with primary bronchogenic carcinoma treated between March 1971 and September 1973.
• Radiation dose administered was 4,000 rad (40 Gy) using split-course accelerated fractionation.
• Patient outcomes, including survival and development of myelitis, were recorded.

Main Results:

• 45 patients (22.5%) survived for more than 11 months.
• Among the long-term survivors, 6 patients (13.3%) developed progressive myelitis.
• The study highlights a significant complication rate associated with this fractionation schedule.

Conclusions:

• Split-course accelerated fractionation for lung cancer presents a trade-off between survival benefit and the risk of myelitis.
• Further investigation into risk factors and mitigation strategies for radiation myelitis is warranted.
• Understanding the factors affecting radiation myelitis is crucial for optimizing treatment protocols.